340 related articles for article (PubMed ID: 30500943)
21. Availability and use of non-prescribed buprenorphine-naloxone in a Canadian setting, 2014-2020.
Bach P; Bawa M; Grant C; Milloy MJ; Hayashi K
Int J Drug Policy; 2022 Mar; 101():103545. PubMed ID: 34875527
[TBL] [Abstract][Full Text] [Related]
22. The Use of Once-monthly Injectable Buprenorphine for the Treatment of Opioid Use Disorder in Postpartum Women: A Case Series.
Shadowen C; Moeller FG; Martin CE
J Addict Med; 2021 Jul-Aug 01; 15(4):292-296. PubMed ID: 34397780
[TBL] [Abstract][Full Text] [Related]
23. Treatment of opioid dependence with buprenorphine: current update.
Soyka M
Dialogues Clin Neurosci; 2017 Sep; 19(3):299-308. PubMed ID: 29302227
[TBL] [Abstract][Full Text] [Related]
24. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.
Greenwald MK; Comer SD; Fiellin DA
Drug Alcohol Depend; 2014 Nov; 144():1-11. PubMed ID: 25179217
[TBL] [Abstract][Full Text] [Related]
25. Update on pharmacotherapy for treatment of opioid use disorder.
Ayanga D; Shorter D; Kosten TR
Expert Opin Pharmacother; 2016 Dec; 17(17):2307-2318. PubMed ID: 27734745
[TBL] [Abstract][Full Text] [Related]
26. Buprenorphine alone or with naloxone: Which is safer?
Kelty E; Cumming C; Troeung L; Hulse G
J Psychopharmacol; 2018 Mar; 32(3):344-352. PubMed ID: 29433352
[TBL] [Abstract][Full Text] [Related]
27. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of multimodal analgesic treatment of severe traumatic acute pain in mice pretreated with chronic high dose of buprenorphine inducing mechanical allodynia.
Coutens B; Derreumaux C; Labaste F; Minville V; Guiard BP; Moulédous L; Bounes V; Roussin A; Frances B
Eur J Pharmacol; 2020 May; 875():172884. PubMed ID: 31870829
[TBL] [Abstract][Full Text] [Related]
29. Patient perspectives on buprenorphine/naloxone treatment in the context of HIV care.
Egan JE; Netherland J; Gass J; Finkelstein R; Weiss L;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S46-53. PubMed ID: 21317594
[TBL] [Abstract][Full Text] [Related]
30. Buprenorphine-naloxone therapy in pain management.
Chen KY; Chen L; Mao J
Anesthesiology; 2014 May; 120(5):1262-74. PubMed ID: 24509068
[TBL] [Abstract][Full Text] [Related]
31. CE: Acute Pain Management for People with Opioid Use Disorder.
Broglio K; Matzo M
Am J Nurs; 2018 Oct; 118(10):30-38. PubMed ID: 30211703
[TBL] [Abstract][Full Text] [Related]
32. The clinical conundrum of perioperative pain management in patients with opioid dependence: lessons from two cases.
Israel JS; Poore SO
Plast Reconstr Surg; 2013 Apr; 131(4):657e-658e. PubMed ID: 23542298
[No Abstract] [Full Text] [Related]
33. Perioperative Continuation of Buprenorphine at Low-Moderate Doses Was Associated with Lower Postoperative Pain Scores and Decreased Outpatient Opioid Dispensing Compared with Buprenorphine Discontinuation.
Quaye A; Potter K; Roth S; Acampora G; Mao J; Zhang Y
Pain Med; 2020 Sep; 21(9):1955-1960. PubMed ID: 32167541
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
[TBL] [Abstract][Full Text] [Related]
35. Buprenorphine/Naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder.
Becker WC; Ganoczy D; Fiellin DA; Bohnert AS
J Subst Abuse Treat; 2015 Jan; 48(1):128-31. PubMed ID: 25312475
[TBL] [Abstract][Full Text] [Related]
36. Approach to buprenorphine use for opioid withdrawal treatment in the emergency setting.
Cisewski DH; Santos C; Koyfman A; Long B
Am J Emerg Med; 2019 Jan; 37(1):143-150. PubMed ID: 30355476
[TBL] [Abstract][Full Text] [Related]
37. Medications for management of opioid use disorder.
Koehl JL; Zimmerman DE; Bridgeman PJ
Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
[TBL] [Abstract][Full Text] [Related]
38. Does Prescription Length of Buprenorphine Influence Treatment Outcomes in Opioid Use Disorder? A Retrospective Cohort Study from North India.
Ghosh A; Mahintamani T; Kathiravan S; Swer SB; Basu D; Mattoo SK; B N S; Singh A
Subst Use Misuse; 2023; 58(12):1620-1624. PubMed ID: 37469041
[TBL] [Abstract][Full Text] [Related]
39. A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration.
Kalluri HV; Zhang H; Caritis SN; Venkataramanan R
Br J Clin Pharmacol; 2017 Nov; 83(11):2458-2473. PubMed ID: 28688108
[TBL] [Abstract][Full Text] [Related]
40. Buprenorphine Microdosing for the Pain and Palliative Care Clinician.
Quirk K; Stevenson M
J Palliat Med; 2022 Jan; 25(1):145-154. PubMed ID: 34978915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
